Investors have questions about the scope of new Trump administration restrictions on U.S.-China biotech deals and their potential impact on cross-border investment.
By the numbers: The SPDR S&P Biotech ETF fell as much as 3% Friday morning, but some Chinese biotech stocks fell more sharply.
